Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

A Unique Mycoplasma Protein Generically Binds All Types of Antibodies and Blocks Antigen Binding

By BiotechDaily International staff writers
Posted on 20 Feb 2014
Image: Protein M, an unusual bacterial protein, attaches to virtually any antibody, possibly helping bacteria establish long-term infections. Compared to thousands of known structures, this protein appears to be unique (Photo courtesy of the Scripps Research Institute).
Image: Protein M, an unusual bacterial protein, attaches to virtually any antibody, possibly helping bacteria establish long-term infections. Compared to thousands of known structures, this protein appears to be unique (Photo courtesy of the Scripps Research Institute).
A team of molecular biologists has isolated a bacterial protein that binds to all types of antibodies and prevents them attaching to their specific antigens.

The novel protein—Protein M—may join the ranks of other nonspecific antibody binding proteins such as Protein A and Protein G as a tool for researchers seeking to purify antibodies from mixtures of other biological molecules.

Investigators at The Scripps Research Institute (La Jolla, CA, USA) discovered Protein M, which was being produced by the primitive bacterium Mycoplasma genitalium, during a study on the relationship between chronic bacterial infection and myeloma.

After isolating the protein, the investigators used X-ray crystallography and other techniques, including electron microscopy, to determine Protein M's three-dimensional atomic structure while the protein was bound to various human antibodies. They reported in the February 7, 2014, issue of the journal Science that the crystal structure of the external domain of transmembrane Protein M differed from other known protein structures, as did its mechanism of antibody binding. Protein M bound with high affinity to all types of human and nonhuman immunoglobulin G, predominantly through attachment to the conserved portions of the variable region of the kappa and gamma light chains. Furthermore, Protein M blocked antibody-antigen binding, likely because of its large C-terminal domain extending over the antibody-combining site, blocking entry to large antigens.

The investigators suggested that the most immediate use for Protein M will likely be as a tool for immobilizing antibodies in mixtures and cell cultures as a preparatory step in the generation of highly purified antibodies for research and drug manufacturing. “It may be the most useful antibody purification device ever found,” said senior author Dr. Richard A. Lerner, professor of immunochemistry at The Scripps Research Institute.

Related Links:

The Scripps Research Institute



Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.